Philip Stevens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Philip Stevens has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Gordon Carlson
Salford Royal NHS Foundation Trust; General Surgery; Stott Lane Salford UK M6 8HD
2 shared publicationsRaymond Delicata
Gwent Healthcare NHS Healthboard ? Nevill Hall Hospital; General Surgery; Brecon Road Abergavenny UK NP7 7EG
2 shared publicationsSimon Lal
Salford Royal Foundation Trust; Intestinal Failure Unit; Salford UK M6 8HD
2 shared publicationsJake S. Hartford-Beynon
1 shared publicationR J Delicata
Department of General Surgery, Nevill Hall Hospital, Brecon Road, Abergavenny NP7 7EG, UK
1 shared publicationRaymond J. Delicata
1 shared publication
Latest Publications
- 3 June 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6
Somatostatin analogues for treatment of enterocutaneous fistula
- 3 June 2019
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6
Somatostatin analogues for treatment of enterocutaneous fistula
- 30 April 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 4
Somatostatin analogues for treatment of enterocutaneous fistula
- 30 April 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 4
Somatostatin analogues for treatment of enterocutaneous fistula
- Open Access
- 1 January 2012
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 94 (1) , 63
Use of Roeder knot with vicryl-reel ligature for laparoscopic appendicectomy: have we forgotten how to tie knots?
- 1 January 2012
- Published by Royal College of Surgeons of England in The Annals of The Royal College of Surgeons of England
- Vol. 94 (1) , 63
Open AccessUse of Roeder knot with vicryl-reel ligature for laparoscopic appendicectomy: have we forgotten how to tie knots?
- 1 October 2011
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 23 (10) , 912-922
Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula
Somatostatin analogues may help pancreatic fistula although it remains unclear whether they help nonpancreatic fistula. This study involved meta-analysis of somatostatin analogues for treatment of enterocutaneous fistula. Meta-analysis of studies was undertaken, to estimate the effect of somatostatin analogues on spontaneous closure, time to closure and mortality. Results showed significant associations between somatostatin and both spontaneous closure rate [odds ratio (OR) 6.61, 95% (CI) confidence interval 1.35-32.43] and time to closure (standardized mean difference -0.80, 95% CI: -1.34 to -0.26). Octreotide reduced closure time (standardized mean difference -0.57, 95% CI: -0.95 to -0.20) but not spontaneous closure (OR: 1.74, 95% CI: 0.64-4.76). Lanreotide also improved time to closure (mean of 17 days vs. 26 days, standard deviation not stated) but not spontaneous closure (OR: 0.94, 95% CI: 0.42-2.12). Somatostatin, octreotide and lanreotide did not significantly affect mortality (OR: 0.30, 0.82, and 0.48; 95% CI: 0.03-3.47, 0.38-1.78, and 0.04-5.07 respectively). Somatostatin and octreotide improved fistula closure time but only somatostatin improved spontaneous closure rate.
- 1 October 2011
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 23 (10) , 912-922
Systematic review and meta-analysis of the role of somatostatin and its analogues in the treatment of enterocutaneous fistula
Somatostatin analogues may help pancreatic fistula although it remains unclear whether they help nonpancreatic fistula. This study involved meta-analysis of somatostatin analogues for treatment of enterocutaneous fistula. Meta-analysis of studies was undertaken, to estimate the effect of somatostatin analogues on spontaneous closure, time to closure and mortality. Results showed significant associations between somatostatin and both spontaneous closure rate [odds ratio (OR) 6.61, 95% (CI) confidence interval 1.35-32.43] and time to closure (standardized mean difference -0.80, 95% CI: -1.34 to -0.26). Octreotide reduced closure time (standardized mean difference -0.57, 95% CI: -0.95 to -0.20) but not spontaneous closure (OR: 1.74, 95% CI: 0.64-4.76). Lanreotide also improved time to closure (mean of 17 days vs. 26 days, standard deviation not stated) but not spontaneous closure (OR: 0.94, 95% CI: 0.42-2.12). Somatostatin, octreotide and lanreotide did not significantly affect mortality (OR: 0.30, 0.82, and 0.48; 95% CI: 0.03-3.47, 0.38-1.78, and 0.04-5.07 respectively). Somatostatin and octreotide improved fistula closure time but only somatostatin improved spontaneous closure rate.
- Open Access
- 14 September 2011
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 98 (12) , 1682-1684
Evidence for using somatostatin analogues in the treatment of enterocutaneous fistula
- 14 September 2011
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 98 (12) , 1682-1684
Open AccessEvidence for using somatostatin analogues in the treatment of enterocutaneous fistula
- 26 August 2009
- Published by Wiley in International Wound Journal
- Vol. 6 (4) , 259-266
Vacuum‐assisted closure of laparostomy wounds: a critical review of the literature
Vacuum‐assisted closure (VAC) reduces the burden for carers of laparostomy wounds but evidence from randomised trials is lacking. This review analyses the evidence for the VAC® abdominal wound management system (KCI, San Antonio, TX) in the open abdomen. Three prospective studies provide level III evidence that VAC® allows delayed primary fascial closure in the majority of these wounds up to 21 days after occurrence, but not where duration of VAC® was less than 9 days or if vacuum pack techniques were used in place of VAC®. Fistulae occurred in a minority of wounds complicated by multi‐organ failure or sepsis and could not be attributed to VAC® itself. Two retrospective analyses suggested VAC® may reduce re‐operation rate and length of stay in complex wounds. Whilst randomised controlled trials remain the gold standard of evidence for effectiveness of health care interventions, contemporaneous level III evidence supports the hypothesis that VAC® increases the rate of primary fascial closure. Whilst enterocutaneous fistula formation is reported in the most complex of these wounds, there is no more evidence that these are consequential to as opposed to coincident with VAC® use.
- 26 August 2009
- Published by Wiley in International Wound Journal
- Vol. 6 (4) , 259-266
Vacuum‐assisted closure of laparostomy wounds: a critical review of the literature
Vacuum‐assisted closure (VAC) reduces the burden for carers of laparostomy wounds but evidence from randomised trials is lacking. This review analyses the evidence for the VAC® abdominal wound management system (KCI, San Antonio, TX) in the open abdomen. Three prospective studies provide level III evidence that VAC® allows delayed primary fascial closure in the majority of these wounds up to 21 days after occurrence, but not where duration of VAC® was less than 9 days or if vacuum pack techniques were used in place of VAC®. Fistulae occurred in a minority of wounds complicated by multi‐organ failure or sepsis and could not be attributed to VAC® itself. Two retrospective analyses suggested VAC® may reduce re‐operation rate and length of stay in complex wounds. Whilst randomised controlled trials remain the gold standard of evidence for effectiveness of health care interventions, contemporaneous level III evidence supports the hypothesis that VAC® increases the rate of primary fascial closure. Whilst enterocutaneous fistula formation is reported in the most complex of these wounds, there is no more evidence that these are consequential to as opposed to coincident with VAC® use.